Updated BLIS agreement strengthens Probi’s portfolio with new exclusivity for oral health probiotic strains in both humans and pets

Probi has reinforced its partnership with BLIS Technologies (BLIS®) through an updated agreement, granting Probi exclusive distribution rights for the probiotic strains BLIS K12™ and BLIS M18™ in the US, Canada, and select EMEA markets for both human and pet health. This positions Probi at the forefront of oral health innovation for a broader range of customers.

Probi and BLIS Technologies have strengthened their long-term strategic partnership through a renewed agreement that extends Probi's exclusivity for the manufacture and distribution of BLIS probiotic strains for human oral health in key markets. It also grants Probi new exclusive rights for pet nutrition, addressing the increasing demand for premium probiotic pet products.

"This reflects the mutual confidence both Probi and BLIS have in the enduring value of our partnership,” says Anita Johansen, CEO of Probi AB. “By extending exclusivity to include pet health, we align our collaboration with the strategic objective of entering the pet health segment. This move responds to the rising demand from pet owners for scientifically supported, well-documented probiotic strains that meet the needs of pets and their families."

“We are excited to deepen our partnership with Probi,” says Scott Johnson, CEO of BLIS Technologies. “This agreement not only strengthens our foothold in human wellbeing but also aligns with the growing opportunity to provide innovative solutions in pet health.”

Probi will showcase its latest research, including the new biotic products targeting pet health, at SupplySide Global 2025, held October 27-30 at Mandalay Bay, Las Vegas. Interested partners, pet health professionals, and media representatives are invited to visit booth #4443 to discover the latest innovations and discuss collaboration opportunities.

Two unique strains that strengthen oral health

• The oral cavity hosts a diverse bacterial community, with Streptococcus species dominating healthy mouths.
• Oral diseases, including cavities and gum disease, disrupt this balance and increase the presence of harmful bacteria.
• Regular hygiene is essential, but some mouthwashes can affect not only harmful bacteria, but also beneficial microbiota.
• Maintaining helpful bacteria supports oral and upper respiratory health.
• Streptococcus salivarius BLIS K12™ and BLIS M18™ have unique properties, supported by multiple clinical studies, showing significant benefits for oral health.

ABOUT BLIS TECHNOLOGIES

Delivering proven health benefits through evidence-based, advanced probiotics.

BLIS Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including ears, nose, and throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand and in Asia, Europe and the USA. More information about BLIS Technologies Ltd can be found at www.blis.co.nz.